75000 - Document - Cover Page
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
link:presentationLink
link:calculationLink
link:definitionLink
75090 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Cash and Investments in Marketable Securities
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Condensed Consolidated Financial Statement Details
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Equity Method Investment
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Stockholders" Equity
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - License and Collaboration Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Restructuring and Impairment
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Impairment of Goodwill
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Cash and Investments in Marketable Securities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Condensed Consolidated Financial Statement Details (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Equity Method Investment (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Restructuring and Impairment (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Equity Method Investment - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Equity Method Investment - Schedule of equity method investment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Commitments and Contingencies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Stockholders' Equity - Summary of Reverse Stock Split, Shares Reserved for Issuance Under Employee Stock Plans (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Stockholders' Equity - Summary of Common Share Data (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Stockholders' Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - License and Collaboration Agreements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Restructuring and Impairment - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Restructuring and Impairment - Summary of Restructuring Plans, Restructuring and Impairment (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Restructuring and Impairment - Sublease Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Restructuring and Impairment - Restructuring Reserve Rollforward (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Segment Reporting - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Segment Reporting - Summary of Significant Expense Categories and Consolidated Net Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Segment Reporting - Schedule of Other Segment Expense Items Included within Net Loss (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Subsequent Event - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Rule10b51ArrModifiedFlag
Rule10b51ArrModifiedFlag
Rule 10b5-1 Arrangement Modified
Segments [Domain]
Restructuring Reserve, Total
Restructuring Reserve
Restructuring reserve, beginning balance
Restructuring reserve, ending balance
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Statement of Financial Position Location, Balance [Domain]
Balance Sheet Location [Domain]
Reverse Stock Split
Reverse Stock Split [Policy Text Block]
Disclosure of reverse stock split policy
Increase (Decrease) in Accounts Payable, Total
Increase (Decrease) in Accounts Payable
Accounts payable
Plan Name [Axis]
Plan Name [Axis]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Investments in continuous unrealized loss positions for 12 months or longer
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options Shares Issued Price Per Unit
Share based compensation arrangement by share based payment award, equity instruments other than options shares issued price per unit.
Share issued base value
Fair Value, Inputs, Level 2 [Member]
Level 2
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Common stock, shares authorized (in shares)
Common stock, number of authorized
Common shares authorized for issuance
Net accounts receivable
Accounts Receivable, after Allowance for Credit Loss
Accounts Receivable, after Allowance for Credit Loss, Total
Effective date of warrant
Effective Date of Warrant
Effective date of warrant.
Product and Service [Axis]
Product and Service [Axis]
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Shell Company
Entity Shell Company
Other Accrued Liabilities, Current
Other accrued expenses
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalent
Cash and cash equivalents
Percentage of ownership received in asset acquisition.
Percentage Of Ownership Received in Asset Acquisition
Ownership interest received
Milestone
Milestone [Domain]
Milestone [Domain]
Total impairment of lease assets
Non-cash impairment charges
Impairment expense for facilities
Impairment charges
Asset acquisition by ampersand capital partners.
Asset Acquisition By Ampersand Capital Partners [Member]
Asset Acquisition By Ampersand Capital Partners
Subsidiary, Sale of Stock [Line Items]
Sale of Facility
Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Huntsville Manufacturing Facility
Common Stock, Shares, Issued
Common stock shares, issued (in shares)
Common shares issued
Asset Class [Domain]
Asset Class [Domain]
Statement [Table]
Statement [Table]
Statement [Line Items]
Statement [Line Items]
Treasury Stock, Value, Acquired, Cost Method
Repurchase of common stock from Bristol-Myers Squibb
Pre Funded Warrant.
Pre Funded Warrant [Member]
Pre-Funded Warrant
Facilities Costs
Facilities costs.
Facilities costs
Entity Filer Category
Entity Filer Category
Liabilities and Equity
Total liabilities and stockholders' equity
Restructuring Type [Axis]
Restructuring Type [Axis]
Prepaid Expenses and Other Current Assets [Member]
Other prepaid expenses
Restructuring and Related Costs [Table Text Block]
Schedule of Restructuring and Impairment
Shares Issued, Price Per Share
Shares issued, price per share
Subsequent Event [Line Items]
Upfront and milestone payments received under license agreement.
Upfront And Milestone Payments Received Under License Agreement
Received upfront and milestone payment
Interest income
Investment Income, Interest
Debt Securities, Available-for-Sale, Noncurrent
Long-term investments
Long-term investments
Percentage of Gross Sale of Common Stock Sold through Sales Agents Commission Rate
Percentage of gross sale of common stock sold through sales agents commission rate.
Percentage of gross sale of common stock sold through sales agents commission rate
RSUs outstanding
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Number
Share based compensation arrangement by share based payment award equity instruments other than option number.
Sale of stock upon exercise of option to purchase additional shares of common stock
Sale Of Stock Upon Exercise Of Option To Purchase Additional Shares Of Common Stock
Sale of stock upon exercise of option to purchase additional shares of common stock.
Additional Paid in Capital, Common Stock
Capital in excess of par value
Rezpegaldesleukin [Member]
Rezpegaldesleukin (cytokine Treg stimulant)
Rezpegaldesleukin.
Related Party [Member]
Related Party
Equity Method Investment Dividends or Distributions per Unit
Equity method investment dividends or distributions per unit.
Equity method investment dividends or distributions per unit
Bristol Myers Squibb Company [Member]
Bristol-Myers Squibb Company.
Bristol Myers Squibb Company
Restructuring Costs and Asset Impairment Charges
Restructuring and impairment
Restructuring and impairment
Contract termination and other costs included in accrued expenses.
Contract Termination and Other Costs Included in Accrued Expenses
Contract termination and other costs included in accrued expenses
Investment, Name [Axis]
Earnings Per Share, Basic, Total
Earnings Per Share, Basic
Basic net loss per share (in dollars per share)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Net foreign currency translation gain (loss)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance
Total common stock reserved for issuance
Stock options outstanding
Liabilities, Current
Total current liabilities
Increase (Decrease) in Accounts Receivable
Accounts receivable
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Parent Company [Member]
Nektar's
Preferred unit, price per unit owned by related party
Preferred Unit, Price Per Unit Owned by Related Party
Preferred unit, price per unit owned by related party.
Equity, Attributable to Parent [Abstract]
Stockholders' equity:
Entity Small Business
Entity Small Business
Payable for newdrug investigle milestone.
Payable For Newdrug Investigle Milestone
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit)
Accumulated deficit
2025 Secondary Public Offering
Two Thousand Twenty Five Secondary Public Offering [Member]
Two thousand twenty five secondary public offering.
Sale of Stock, Price Per Share
Offering per share price
Other.
Other Partner [Member]
Other Partner
Share-Based Payment Arrangement [Text Block]
Stock-Based Compensation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Amendment Flag
Amendment Flag
Product and Service [Domain]
Product and Service [Domain]
Inventory Disclosure [Text Block]
Condensed Consolidated Financial Statement Details
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of warrants issued to be purchase common shares
Earnings Per Share, Policy [Policy Text Block]
Net Loss per Share
Treasury stock policy.
Treasury Stock [Policy Text Block]
Treasury Stock
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
Operating Lease, Measurement Input
Operating Lease, Measurement Input
Operating lease, measurement input
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Purchase and Sale Agreement 2020
Purchase and Sale Agreement 2020 [Member]
2020 Purchase and Sale Agreement
Common Stock [Member]
Common Shares
Common Stock
Amortization of premiums (discounts), net
Amortization of Debt Discount (Premium)
Amortization of premiums (discounts), net
Stock Issued During Period, Shares, Prefunded Warrant Exercise
Stock issued during period, shares, prefunded warrant exercise.
Shares issued under prefunded warrant exercise (in shares)
Portion at Fair Value Measurement [Member] [Default]
Portion at Fair Value Measurement [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV
Measurement Input, Market Participant Subtenant Borrowing Rate
Measurement Input, Market Participant Subtenant Borrowing Rate [Member]
Measurement Input, Market Participant Subtenant Borrowing Rate
Income Tax, Policy [Policy Text Block]
Income Taxes
Name of Property [Axis]
Name of Property [Axis]
Biolojic design company.
Biolojic Design Company [Member]
Biolojic Design Member
Statement of Financial Position Location, Balance [Axis]
Balance Sheet Location [Axis]
Operating Lease, Right-of-Use Asset
Operating lease right-of-use assets
Payments to Acquire Debt Securities, Available-for-Sale
Purchases of investments
Inventory Disclosure [Abstract]
Inventory Disclosure [Abstract]
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Net unrealized gain (loss) on available-for-sale securities
Class of Warrant or Right [Axis]
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Amended and restated two thousand seventeen performance incentive plan.
Amended And Restated Two Thousand Seventeen Performance Incentive Plan [Member]
Amended and Restated 2017 Performance Incentive Plan
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Net decrease in cash and cash equivalents
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Subsequent Event Type [Domain]
Loss on Contract Termination
Contract termination and other restructuring costs
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Potentially dilutive securities (in shares)
Disposal Group Classification [Domain]
Common Stock, Par or Stated Value Per Share
Common stock, par value (in dollars per share)
Unrecorded Unconditional Purchase Obligation, Purchases
Purchases made
Proceeds from Issuance of Warrants
Proceeds from issuance of pre-funded warrant
Goodwill [Line Items]
Goodwill [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost
Amortized Cost
Debt Securities, Available-for-Sale, Total
Debt Securities, Available-for-Sale
Fair Value
Asset Impairment Charges [Text Block]
Impairment of Goodwill
Organization and summary of significant accounting policies.
Organization And Summary Of Significant Accounting Policies [Table]
Organization And Summary Of Significant Accounting Policies [Table]
Estimate of Fair Value Measurement [Member]
Estimate of Fair Value Measurement
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Estimated Fair Value at
Accrued Liabilities, Current
Total accrued expenses
Net payable
Accrued expenses (including $316 and $3,403 as of September 30, 2025 and December 31, 2024, respectively, to a related party)
Cost of Sales [Member]
Cost of goods sold
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Current Fiscal Year End Date
Current Fiscal Year End Date
TCG Crossover Fund II, L.P.
TCG Crossover Fund I I, L P [Member]
TCG Crossover Fund II, L.P.
Document Quarterly Report
Document Quarterly Report
Other Cost and Expense, Operating
Other operating costs
Provision for inventory obsolescence
Provision For Inventory Obsolescence
Provision for inventory obsolescence.
Provision for net realizable value of inventory
Entity Address, State or Province
Entity Address, State or Province
Increase (Decrease) in Other Accrued Liabilities
Accrued expenses
Investment, Name [Domain]
Asset Acquisition [Domain]
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding (in shares)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income (loss)
Comprehensive loss
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Gross Unrealized Gains
Total common stock reserved for issuance
Common Stock, Capital Shares Reserved for Future Issuance
Common stock reserved for issuance
Total shares reserved for issuance under our employee stock plans
Class of Warrant or Right [Domain]
Commissions Due To Offering
Commissions due to offering.
Commissions
Contract Termination and Other Costs [Member[
Contract Termination and Other Costs [Member[
Contract Termination and Other Costs
Accounts Receivable [Member]
Interest and other non-trade receivables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Schedule of Stock-Based Compensation Expense
Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options Shares Issued
Share based compensation arrangement by share-based payment award, equity instruments other than options shares issued.
Shares issued
Collaborative Arrangement Disclosure [Text Block]
License and Collaboration Agreements
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Sublease Property, Plant And Equipment
Sublease Property, Plant And Equipment [Member]
Property, Plant and Equipment
Subsequent Event [Member]
Subsequent Event
Contract Termination Costs
Contract termination costs.
Contract termination costs
Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities
Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities
Operating leases, net
Other Assets, Noncurrent
Other assets
Debt Securities, Available-for-Sale, Current
Short-term investments
Antidilutive Securities [Axis]
Antidilutive Securities
Accumulated Other Comprehensive Income
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income/(Loss)
Treasury Stock, Common, Shares
Treasury Stock, Common, Shares
Ending balance (in shares)
Beginning balance (in shares)
Treasury shares outstanding
Non-cash interest expense on liabilities related to the sales of future royalties
Non-cash interest expense related to sale of royalties.
Non Cash Interest Expense Related To Sale Of Royalties
Non-cash interest expense
Non-cash interest expense on liabilities related to the sales of future royalties
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Preferred Stock, Value, Issued
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at September 30, 2025 or December 31, 2024, respectively
Minimum [Member]
Minimum
Bristol Myers Squibb collaboration agreement.
Bristol Myers Squibb Collaboration Agreement [Member]
Bristol Myers Squibb Collaboration Agreement
Financial Instrument [Axis]
Financial Instrument [Axis]
Assets, Current [Abstract]
Current assets:
Two Thousand Twenty Five Public Offering [Member]
Two thousand twenty five public offering.
2025 Offering
Fair Value, Inputs, Level 3 [Member]
Fair Value, Level 3
Segment Reporting [Abstract]
NonRule10b51ArrModifiedFlag
NonRule10b51ArrModifiedFlag
Non-Rule 10b5-1 Arrangement Modified
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Schedule of Portfolio of Cash and Investments in Marketable Securities
Liabilities, Current [Abstract]
Current liabilities:
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options Reserved For Issuance
Share-based compensation arrangement by share-based payment award, equity instruments other than options reserved for issuance.
Shares reserved for issuance
Product [Member]
Product sales
Discovery Research and Other Programs
Discovery Research And Other Programs [Member]
Discovery research and other programs.
Third St. Facility
Third St. Facility [Member]
Third St. Facility
Services Agreements
Services Agreements [Member]
Services agreements.
Proceeds from sale of future royalties
Proceeds From Sale of Future Royalties.
Proceeds From Sale of Future Royalties
Upfront and milestone payments received from license agreements.
Upfront And Milestone Payments Received From License Agreements
Upfront and milestone payments received from license agreements
Securities Purchase Agreement.
Securities Purchase Agreement [Member]
Securities Purchase Agreement
Commitments and Contingencies
Commitments and contingencies
Percentage of preferred units outstanding
Percentage Of Preferred Units Outstanding
Percentage of preferred units outstanding.
Milestone [Axis]
Milestone [Axis]
Milestone [Axis]
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture
Shares issued under equity compensation plans (in shares)
Accounts Receivable, Credit Loss Expense (Reversal)
Accounts receivable, credit loss expense (reversal)
General and Administrative Expense [Member]
General and administrative
Percentage of the preferred units owned by related party outstanding
Percentage of Preferred Units Owned by Related Party Outstanding
Percentage of preferred units owned by related party outstanding.
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]
Restructuring
Shares Remained Available For Issuance Under Warrant
Shares remained available for issuance under warrant.
Shares remained available for issuance under warrant
Reverse stock split
Stockholders' Equity, Reverse Stock Split
NKTR Two Five Five [Member]
NKTR two five five.
NKTR-255 (IL-15 receptor agonist)
Sale of Equity Aggregate Maximum Public Offering Amount
Sale of equity aggregate maximum public offering amount.
Aggregate maximum public offering amount
Percentage of the common units outstanding
Percentage of the common units outstanding
Percentage of the common units outstanding
Common units owned
Common units owned
Common units owned
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Weighted average shares outstanding used in computing basic net loss per share (in shares)
Preferred stock, shares designated.
Preferred Stock Share Designated
Preferred stock, shares designated (in shares)
Segments [Axis]
Cash, restricted cash, cash equivalents, and available for sale investments.
Cash Restricted Cash Cash Equivalents And Available For Sale Investments
Cash and investments in marketable securities
Total cash and investments in marketable securities
Subsequent Events [Text Block]
Subsequent Events
Cash
Cash
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
Equity, Attributable to Parent
Ending balance
Beginning balance
Total stockholders' equity
Available For Sale Securities In Unrealized Loss Positions Number Of Positions Less Than One Year
Available for sale securities in unrealized loss positions number of positions less than one year.
Number of investments in unrealized loss positions
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value (in dollars per share)
Stock Options, RSUs And PSUs
Stock Options, RSUs And PSUs [Member]
Stock Options, RSUs And PSUs
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Equity Method Investments
Equity method investment in Gannet BioChem
Type of Restructuring [Domain]
Type of Restructuring [Domain]
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Equity Method Investment [Table]
Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure
Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure
Property, plant and equipment and operating lease right-of-use assets
Treasury Stock, Common [Member]
Treasury Stock
Claim on net assets of Gannet BioChem - end of period
Equity Method Investment, Underlying Equity in Net Assets
Claim on net assets of Gannet BioChem - beginning of period
Claim on net assets of Gannet BioChem
2022 and 2023 Restructuring Plans
Two Thousand Twenty Two and Two Thousand Twenty Three Restructuring Plans [Member]
Two thousand twenty two and two thousand twenty three restructuring plans.
Employee Stock Purchase Plan
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan
Accrued clinical trial expenses current.
Accrued Clinical Trial Expenses Current
Accrued clinical trial expenses
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued Expenses
Purchase and Sale Agreement 2012
Purchase and Sale Agreement 2012 [Member]
2012 Purchase and Sale Agreement
Other Assets, Current
Other current assets
Other current assets (including $177 and $0 as of September 30, 2025 and December 31, 2024, respectively, from a related party)
Loss from equity method investment
Change in claim on net assets of Gannet BioChem
Loss from equity method investment
Resale of common stock issuable upon exercise of warrant
Resale of Common Stock Issuable Upon Exercise of Warrant
Resale of common stock issuable upon exercise of warrant.
Mission Bay Facility
Mission Bay Facility [Member]
Mission Bay Facility
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Other segment expenses
Total other segment expenses
Segment Reporting, Other Segment Item, Amount
Plan Name [Domain]
Plan Name [Domain]
Increase (Decrease) in Other Operating Assets, Total
Increase (Decrease) in Other Operating Assets
Other assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Entity [Domain]
Entity [Domain]
Liabilities On Sale Of Future Royalties Amortized Transaction Costs
Liabilities On Sale Of Future Royalties Amortized Transaction Costs
Amortization of transaction costs
Agreement term
Agreement term
Agreement term
Cost of Goods and Services Sold, Total
Cost of Product and Service Sold
Cost of goods sold
NKTR Zero One Six Five [Member]
NKTR zero one six five.
NKTR-0165 (tumor necrosis factor receptor type II agonist)
Total impairment of right-of-use assets
Impairment, Long-Lived Asset, Held-for-Use
Impairment of other property, plant and equipment
Total impairment of right-of-use assets and property, plant and equipment
Impairment of right-of-use assets and property and equipment
Certificates of Deposit [Member]
Certificates of deposit
Jonathan Zalevsky [Member]
Jonathan zalevsky.
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]
Treasury Stock, Value, Total
Treasury Stock, Value
Treasury stock, at cost; 552,307 shares as of June 30, 2025 and December 31, 2024, respectively
Treasury stock, at cost; 0 shares and 552,307 shares as of September 30, 2025 and December 31, 2024, respectively
Restructuring Plan [Axis]
Restructuring Plan [Axis]
Related and Nonrelated Parties [Axis]
Entity Address, City or Town
Entity Address, City or Town
Potential development and regulatory milestones.
Potential Development And Regulatory Milestones
Potential future additional development and regulatory milestones (up to)
Stock Repurchased During Period, Shares
Sale of stock shares repurchased
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Security Exchange Name
Security Exchange Name
Counterparty Name [Axis]
Counterparty Name
Nektar-358
Nektar-358 [Member]
Nektar-358
Measurement Input Type [Domain]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name
Nektar 214.
Nektar 214 [Member]
Nektar 214
Share purchase agreement.
Share Purchase Agreement [Member]
Purchase Agreement
Underwriting Discounts Due To Offering
Underwriting discounts due to offering.
Underwriting discounts
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash and cash equivalents at end of period
Cash and cash equivalents at beginning of period
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Measurement Basis [Axis]
Statistical Measurement [Domain]
Statistical Measurement [Domain]
Class of Warrant or Right, Exercise Price of Warrants or Rights
Exercise price of warrants
Assets, Current
Total current assets
Share-Based Payment Arrangement, Expense
Stock-based compensation
Total stock-based compensation
Document Period End Date
Document Period End Date
Equity Method Investments and Joint Ventures [Abstract]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Fair Value, Level 3
Restructuring Plan
Restructuring Plan [Member]
Restructuring plan.
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs) [Member]
RSUs
Restructuring, Impairment, and Other Activities Disclosure [Text Block]
Restructuring and Impairment
Liabilities
Total liabilities
Financial Instruments [Domain]
Financial Instruments [Domain]
Equity Method Investment
Equity Method Investments [Policy Text Block]
License and collaboration agreements.
License And Collaboration Agreements [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]
Milestone One [Member]
Milestone One [Member]
Milestone One
Asset Purchase Agreement
Asset purchase agreement.
Asset Purchase Agreement [Member]
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted Average Number of Shares Outstanding, Diluted
Weighted average shares outstanding used in computing diluted net loss per share (in shares)
Entity File Number
Entity File Number
Number Of Milestones
Number Of Milestones
Number of Milestone
Sublease Operating Lease Right of Use Assets
Sublease Operating Lease Right of Use Assets [Member]
Operating Lease Right-of-Use Assets
Cover [Abstract]
Cover page.
Measurement Input Type [Axis]
Measurement Input Type [Axis]
Royalties Liability, Measurement Input
Royalties Liability, Measurement Input
Royalties liability discount rate
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss before provision (benefit) for income taxes and equity method investment
Loss before provision (benefit) for income taxes and equity method investment
Sale of Stock [Domain]
Sale of Stock [Domain]
License collaboration and other revenue.
License Collaboration And Other Revenue [Member]
License, collaboration and other revenue
Warrant exercised prior notice period.
Warrant Exercised Prior Notice Period
Warrant exercised prior notice period
Segment Reporting
Segment Reporting Disclosure [Text Block]
General and Administrative Expense, Total
General and Administrative Expense
General and administrative
Subsequent Event [Table]
Organization and summary of significant accounting policies.
Organization And Summary Of Significant Accounting Policies [Line Items]
Organization And Summary Of Significant Accounting Policies [Line Items]
Restructuring Charges, Total
Restructuring Charges
Restructuring, impairment, and costs of terminated program
Expense recognized during the period
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
Income Loss Before Equity Method Investment
Income (loss) before equity method investment.
Loss before equity method investment
Loss before equity method investment
Interest and Other Non-trade Receivables [Member]
Interest and other non-trade receivables.
Interest and other non-trade receivables
Reported Value Measurement
Reported Value Measurement [Member]
Eli Lilly and Company.
Eli Lilly And Company [Member]
Eli Lilly And Company
Prepaid Research And Development Expenses
Prepaid Research And Development Expenses [Member]
Prepaid research and development expenses
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
Organization and Summary of Significant Accounting Policies
Common Stock, Shares, Outstanding
Ending balance (in shares)
Beginning balance (in shares)
Common stock, shares outstanding (in shares)
Common shares outstanding
Operating Lease, Liability, Current
Operating lease liabilities, current portion
Payment of transaction costs and working capital adjustment from the sale of the Huntsville manufacturing facility
Payment of Transaction Costs and Working Capital Adjustment from the Sale of Manufacturing Facility
Payment of transaction costs and working capital adjustment from the sale of manufacturing facility.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued research and development expenses
Accrued Research And Development Expenses Current
Accrued research and development expenses current.
Document Transition Report
Document Transition Report
Research and Development Expense, Total
Research and development
Research and development expenses
Research and development (including $421 and $0 for the three months ended September 30, 2025 and 2024, respectively, from a related party; and $1,242 and $0 for the nine months ended September 30, 2025 and 2024, respectively, from a related party)
Payments for Repurchase of Common Stock
Repurchase of common stock from Bristol-Myers Squibb
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Stock Issued During Period, Value, New Issues
Shares issued under offering, net of underwriting discounts and offering costs
Equity [Text Block]
Stockholders' Equity
Shares, Issued
Shares issued (in shares)
Net loss
Net loss
Increase (Decrease) in Inventories, Total
Increase (Decrease) in Inventories
Inventory
Gannet BioChem
Gannet Bio Chem [Member]
Gannet bio chem.
Assets [Abstract]
ASSETS
Underwritten by Jefferies LLC
Jefferies LLC [Member]
Jefferies LLC.
Name of Property [Domain]
Name of Property [Domain]
Preferred Units Owned by a Related Party
Preferred units owned by a related party.
Preferred units owned by a related party
Sales Agreement [Member]
Sales agreement.
Sales Agreement
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Cash flows from investing activities:
Accounts Payable, Current, Total
Accounts Payable, Current
Accounts payable
Research and Development Expense [Member]
Research and Development Expense
Research and development
Other Operating Segment [Member]
Other Segment
Schedule Of Liability Related To Sale Of Potential Future Royalties
Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]
Schedule of Liability Related to Sale of Potential Future Royalties
Repayment due of GST refunds
Goods And Service Tax Refunds Repayment Due
Goods and service tax refunds repayment due.
Proceeds from sale of assets
Proceeds from Sale of Productive Assets, Total
Proceeds from Sale of Productive Assets
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture
Shares issued under equity compensation plans
Restructuring Cost and Reserve [Line Items]
Restructuring Cost and Reserve [Line Items]
Payment for development milestones.
Payment For Development Milestones
Common unit, price per unit
Common unit, price per unit
Common unit, price per unit
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Non-cash royalty revenue related to sale of future royalties.
Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]
Non-cash royalty revenue related to the sales of future royalties
Non-cash royalty revenue related to the sales of future royalties
Accrued Contract Termination Costs, Current
Accrued Contract Termination Costs, Current
Accrued contract termination costs
Share-Based Payment Arrangement [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Sale of Stock [Axis]
Sale of Stock [Axis]
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised
Proceeds from shares issued under equity compensation plans and other
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Equity Method Investment
Nektar 0165
Nektar 0165.
Nektar 0165 [Member]
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by (used in) investing activities
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Money Market Funds [Member]
Money market funds
Related and Nonrelated Parties [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
At the Market Offering [Member]
At the Market Offering [Member]
At-the-Market Offering
Other Liabilities, Noncurrent
Other long-term liabilities
Consolidated Entities [Axis]
Consolidated Entities [Axis]
Restructuring Plan [Domain]
Restructuring Plan [Domain]
Legal Entity [Axis]
Legal Entity [Axis]
Liability related to sale of potential future royalties non current net of issuance costs.
Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
Liabilities related to the sales of future royalties, net
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance
Weighted average exercise price
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Additional Paid-in Capital [Member]
Capital in Excess of Par Value
Statement of Income Location, Balance [Axis]
Income Statement Location [Axis]
Change in Accounting Principle, Accounting Standards Update, Adoption Date
Trading Symbol
Trading Symbol
Equity Method Investments, Fair Value Disclosure
Fair value of investment
Sale of stock consideration received.
Sale Of Stock Consideration Received
Sale of stock consideration received
Subsequent Event Type [Axis]
Employee-related Liabilities, Current, Total
Employee-related Liabilities, Current
Accrued compensation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Cash flows from financing activities:
Schedule of Equity Method Investments [Line Items]
Equity Components [Axis]
Equity Components
Nonoperating Income (Expense)
Total non-operating income (expense), net
Equity Component [Domain]
Equity Component
Asset Class [Axis]
Asset Class [Axis]
Sale of Manufacturing Facility
Sale of manufacturing facility.
Sale Of Manufacturing Facility [Policy Text Block]
Goodwill and Intangible Assets Disclosure [Abstract]
Number of operating business segment.
Number Of Operating Business Segment
Number of operating business segment
Depreciation, Depletion and Amortization, Nonproduction, Total
Depreciation, Depletion and Amortization, Nonproduction
Depreciation and amortization expense
Statement of Comprehensive Income [Abstract]
Statement of Comprehensive Income [Abstract]
Maximum
Maximum [Member]
Statistical Measurement [Axis]
Statistical Measurement [Axis]
Segment, Reconciliation of Other Items from Segments to Consolidated [Table]
Common Stock, Value, Issued
Common stock, $0.0001 par value; 390,000,000 shares and 300,000,000 shares authorized at September 30, 2025 and December 31, 2024; 19,652,513 shares and 12,937,308 shares issued at September 30, 2025 and December 31, 2024, respectively; 19,652,513 shares and 12,385,001 shares outstanding at September 30, 2025 and December 31, 2024, respectively
Consolidation, Policy [Policy Text Block]
Basis of Presentation and Principles of Consolidation
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Long-Lived Asset Impairment
Accrued Liabilities
Accrued Liabilities, Total
Net payable
Secondary Offering [Member]
Secondary offering.
Secondary Offering
Preferred Stock, Shares Authorized
Preferred stock, shares authorized (in shares)
Costs and Expenses
Total operating costs and expenses
Proceeds from sale of royalty rights
Proceeds From Sale Of Potential Future Royalties Gross
Proceeds from sale of potential future royalties gross.
Payment of transaction related to purchase and sale agreement
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved
Cash, Cash Equivalent, and Investment [Table Text Block]
Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents
Summary Of Reverse Stock Split, Shares Reserved For Issuance Under Employee Stock Plans [Table Text Block]
Tabular disclosure Of reverse stock split, shares reserved for issuance under employee stock plans.
Summary of Reverse Stock Split, Shares Reserved for Issuance Under Employee Stock Plans
Entity Registrant Name
Entity Registrant Name
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross unrealized losses
Gross Unrealized Losses
Treasury Stock, Shares, Acquired
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Repurchase of common stock from Bristol-Myers Squibb (in shares)
Treasury stock reissued
Other Nonoperating Income (Expense), Total
Other income (expense), net
Other income
Other income
Other income (expense), net (including income of $190 and $0 for the three months ended September 30, 2025 and 2024, respectively, from a related party; and income of $1,051 and $0 for the nine months ended September 30, 2025 and 2024, respectively, from a related party)
Subsequent Events [Abstract]
Schedule Of Equity Method Investments
Schedule Of Equity Method Investments [Table Text Block]
Schedule of equity method investments.
Consolidated Entities [Domain]
Consolidated Entities [Domain]
Provision (benefit) for income taxes
Income Tax Expense (Benefit), Total
Income Tax Expense (Benefit)
Benefit for income taxes
Restructuring Reserve [Roll Forward]
Restructuring Reserve [Roll Forward]
Gross proceeds
Net proceeds from issuance of common stock
Proceeds from offering, net
Costs and Expenses [Abstract]
Operating costs and expenses:
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Significant Concentrations
Disposal Group Classification [Axis]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive income (loss)
Percentage of number of shares of warrant exercised.
Percentage of Number of Shares for Warrant Exercised
Percentage of number of shares of warrant exercised
Payments for Restructuring
Payments during the period
Payments during the period
Payments to Acquire Property, Plant, and Equipment, Total
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Assets
Total assets
Income Statement [Abstract]
Income Statement [Abstract]
Restructuring Cost [Table]
Schedule of Restructuring and Related Costs [Table]
Related Parties
Related Parties [Policy Text Block]
Related parties.
Cash, Cash Equivalent, and Marketable Security [Text Block]
Cash and Investments in Marketable Securities
Stock Issued During Period, Shares, New Issues
Sale and issuance of shares
Shares issued under offering, net of underwriting discounts and offering costs (in shares)
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Diluted net loss per share (in dollars per share)
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Summary of Significant Expense Categories and Consolidated Net Loss
Payment of transaction related to purchase and sale agreement if threshold is not achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved
Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved
Asset Acquisition [Axis]
Non cash royalty revenue related to sale future royalties.
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non-cash royalty revenue related to the sales of future royalties
Non-cash royalty revenue
City Area Code
City Area Code
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income (loss)
Potential development milestones.
Potential Development Milestones
Potential future additional payments for development milestones
Potential Development Milestones
Howard W. Robin [Member]
Howard W. Robin.
Counterparty Name [Domain]
Counterparty Name [Domain]
Segment Reporting Information [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio
Reverse stock split, ratio
Two Thousand Seventeen Performance Incentive Plan
Two Thousand Seventeen Performance Incentive Plan [Member]
2017 Performance Incentive Plan
Equity method investment dividends or distributions
Proceeds from Equity Method Investment, Distribution
Property, Plant and Equipment, Net
Property, plant and equipment, net
Property, plant and equipment, net
Property and equipment, net
Operating Income (Loss)
Loss from operations
Issuance of prefunded warrant
Issuance of prefunded warrant
Issuance of prefunded warrant
Retained Earnings [Member]
Accumulated Deficit
Amount exchanged to remove cap on royalties
Amount exchanged to remove cap on royalties
Amount exchanged to remove cap on royalties
Consideration in cash, net of transaction costs
Asset Acquisition, Consideration Transferred
Asset Acquisition, Consideration Transferred, Total
Payments of Stock Issuance Costs
Commissions
Payments of offering costs associated with issuance of common stock
Underwriting discounts, commissions and offering costs
Minimum purchase commitments
Unrecorded Unconditional Purchase Obligation
Unrecorded Unconditional Purchase Obligation, Including Lease Not yet Commenced, Total
Unrecorded Unconditional Purchase Obligation, Total
Operating Lease, Liability, Noncurrent
Operating lease liabilities, less current portion
Fair Value, Inputs, Level 1 [Member]
Level 1
Class of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by financing activities
Underwritten Public Offering [Member]
Underwritten public offering.
2025 Offering
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]
Liability Related To Sale Of Potential Future Royalties Non Current
Liability Related To Sale Of Potential Future Royalties Non Current
Liabilities related to the sales of future royalties, net – ending balance
Liabilities related to the sales of future royalties, net – beginning balance
Investments, Fair Value Disclosure, Total
Investments, Fair Value Disclosure
Investments, fair value disclosure
Investments in marketable securities
Schedule of Other Current Assets [Table Text Block]
Schedule of Other Current Assets
Nonoperating Income (Expense) [Abstract]
Non-operating income (expense):
Goodwill [Table]
Schedule of Goodwill [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Estimated Litigation Liability
Liability for litigation
Corporate Debt Securities [Member]
Corporate notes and bonds
Entity Interactive Data Current
Entity Interactive Data Current
Statement of Income Location, Balance [Domain]
Income Statement Location [Domain]
Fair Value Measurement [Domain]
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Cash flows from operating activities:
Segment, Reconciliation of Other Items from Segments to Consolidated [Table Text Block]
Schedule of Other Segment Expense Items Included within Net Loss
Organization.
Organization Policy [Text Block]
Organization
Liability to Collaboration Partners, Current
Liability to Collaboration Partners, Current
Liability to collaboration partners
Entity Tax Identification Number
Entity Tax Identification Number
Revenues [Abstract]
Revenue:
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale
Maturities of investments
Clinical Development Contract Manufacturing And Other Third Party Costs
Clinical development contract manufacturing and other third party costs.
Clinical development, contract manufacturing and other third party costs
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Effect of foreign exchange rates on cash and cash equivalents
Employee costs
Employee Related Costs
Employee related costs.
Local Phone Number
Local Phone Number
Sale of stock repurchased cash consideration.
Sale Of Stock Repurchased Cash Consideration
Sale of stock repurchased cash consideration
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Total revenue
Commercial Paper [Member]
Corporate commercial paper
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares remained available for grant
Affiliated Entity [Member]
Affiliates
Stock, Class of Stock [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company